Experimental treatments are now attempting to neutralize neurodegenerative diseases before symptoms ever appear
Experimental immunotherapies are targeting the toxic proteins associated with Amyotrophic Lateral Sclerosis years before symptoms manifest, shifting the focus of neurodegenerative medicine from palliative care to early-stage prevention.
Clinical trials are currently testing whether aggressive immunotherapy can neutralize the pathogenic proteins responsible for Amyotrophic Lateral Sclerosis (ALS) in asymptomatic carriers of the SOD1 genetic mutation. This paradigm shift is exemplified by the Atlas study, which monitors individuals with high genetic risk for biomarkers of neurodegeneration, such as elevated neurofilament light chain levels, before physical paralysis begins.
Continue Reading in App
1 more paragraph · plus a 2-question quiz